Novavax bid for full approval of COVID vaccine stymied by FDA - report
The U.S. FDA has missed a key deadline to decide whether to grant full approval to Novavax's (NASDAQ:NVAX) COVID-19 vaccine.
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Novavax call volume above normal and directionally bullish
Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.
Zacks Investment Research on MSN4d
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Novavax believes BLA ‘ready for approval,’ waiting on action from FDA
Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...
1NVAX, SNY : Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Novavax Inc. stock underperforms Thursday when compared to competitors
Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...
The Pharma Letter22h
$175 million milestone in jeopardy as FDA delays Novavax nod
US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...
Novavax set to snap six days of losses as shares trade in green
Novavax (NVAX) stock rebounds 2.5% after six days of losses amid FDA approval delays for its COVID-19 vaccine.
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.
Novavax (NasdaqGS:NVAX) Sees 21% Weekly Drop As Leadership Changes Shake Market
Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
The health agency’s top immunization official announced the move Monday in protest, citing Secretary Kennedy’s ...